SCYX SCYNEXIS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1178253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY544.0%
TTM net income YoY60.1%
TTM EPS YoY127.8%
Revenue 3-yr CAGR-48.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-126.9%
Net margin-53.5%
FCF margin—
EBITDA margin—
Returns
ROE-21.2%
ROA-17.0%
ROIC (approx.)-52.4%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio3.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $235,000 | $0 | $18.65M | $334,000 | $1.36M | $257,000 | $977,000 |
| R&D expense | $6.20M | $3.89M | $12.35M | $4.54M | $5.45M | $7.14M | $5.14M | $4.31M |
| SG&A expense | $3.56M | $4.12M | $4.59M | $3.58M | $3.29M | $3.78M | $3.73M | $4.72M |
| Operating income | -$9.76M | -$7.78M | -$16.94M | $10.52M | -$8.40M | -$9.56M | -$8.61M | -$8.05M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $173,000 | $211,000 |
| Pretax income | — | — | — | $12.26M | -$8.59M | -$6.88M | -$5.39M | -$4.41M |
| Income tax | — | — | — | $0 | $0 | $0 | $0 | $23,000 |
| Net income | -$8.46M | $7.40M | -$21.30M | $12.26M | -$8.59M | -$6.88M | -$5.39M | -$4.43M |
| EBITDA | — | — | — | — | — | — | — | -$8.05M |
| EPS (basic) | -0.71 | 0.63 | -0.42 | — | -1.38 | -1.11 | -0.11 | — |
| EPS (diluted) | -0.71 | 0.63 | -0.42 | — | -1.38 | -1.11 | -0.11 | — |
| Weighted avg. shares (diluted) | 11.84M | 11.82M | 50.96M | — | 6.24M | 6.22M | 49.44M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.23M | $10.49M | $36.67M | $21.26M | $14.99M | $11.26M | $7.49M | $16.59M |
| Short-term investments | $38.94M | $43.60M | $22.59M | $18.77M | $23.13M | $33.77M | $33.66M | $43.25M |
| Current assets | $50.36M | $56.24M | $62.69M | $40.37M | $48.69M | $56.50M | $52.22M | $72.18M |
| Total assets | $67.95M | $74.97M | $77.63M | $59.03M | $51.07M | $60.69M | $67.92M | $90.64M |
| Current liabilities | $6.65M | $5.83M | $15.90M | $5.73M | $8.47M | $10.86M | $8.96M | $24.10M |
| Total liabilities | $8.90M | $8.04M | $36.32M | $9.65M | $14.64M | $16.23M | $17.38M | $35.57M |
| Shareholders' equity | $59.05M | $66.93M | $41.31M | $49.38M | $36.43M | $44.47M | $50.53M | $55.08M |
| Shares outstanding | 9.95M | 9.95M | 62.05M | 5.44M | 41.96M | 39.17M | 39.02M | 37.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.47M | -$14.88M | -$8.10M | $18.40M | -$8.72M | -$7.50M | -$7.46M | -$9.91M |
| Investing cash flow | $5.80M | -$24.76M | -$525,000 | -$11.82M | $12.42M | $11.27M | $12.44M | -$2.62M |
| Financing cash flow | -$593,000 | $13.46M | $24.04M | -$115,000 | $29,000 | $0 | -$14.08M | -$155,000 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $562,000 | $568,000 | $580,000 | $687,000 | $526,000 | $820,000 | $819,000 | $981,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.